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INTRODUCTION
Transcription factor mutation is a major cause of cell fate dysregulation in leukemia. Indeed many key regulators of hematopoiesis were identified through analysis of leukemia patients. 1 Myelodysplastic syndromes (MDS) by contrast, are acquired clonal diseases regarded broadly as 'pre-leukemic' conditions that can be conservatively managed. However, approximately 10% of all MDS cases evolve into acute myeloid leukemia (AML) within the course of two years. 2 Key challenges in the field are to understand how individual regulators control cell fate at the level of lineage choice, self-renewal, cell cycle or survival, how different regulators interact in transcriptional networks and how circuit behavior is altered in leukemia. 3, 4 Transcription factor GFI1B was identified by sequence homology with oncogene GFI1 (Growth Factor Independence 1). 5 Both GFI1 and GFI1B have six Cterminal C2H2 zinc-fingers and an N-terminal SNAG transcriptional repression domain. [5] [6] [7] In mice, Gfi1 is essential for neutrophil differentiation 8, 9 and in humans severe congenital neutropenia is associated with mutations in GFI1. 10 Gfi1 is also required for B and T lymphopoiesis. 11, 12 In contrast knockout mice have demonstrated that Gfi1b is required for development of both erythroid and megakaryocytic lineages, 13 but the mechanism is not understood. 14 Loss of Gfi1b in adult mice increases absolute numbers of hematopoietic stem cells (HSC), these are less quiescent than wild type HSCs. 15 In partial agreement with the mouse models, human congenital mutations of GFI1B produce hemorrhagic conditions with abnormal platelet function. 16, 17 Against this backdrop, we have studied a previously unreported acquired point mutation (D262N) in the transcription factor GFI1B in a patient with AML arising from an antecedent MDS and explored its biological properties.
This mutation leads to an amino acid change in the fourth zinc finger domain and results in a mutant protein that when expressed in normal human Common
Myeloid Progenitors (CMPs) skews lineage output towards myelopoiesis.
Expression of GFI1B (D262N) in human bone marrow (BM) cells from healthy individuals and other MDS patients promotes their survival. We show that these effects are mediated by upregulation of SPI1 (PU.1).
SPI1 is a critical factor in blood cell differentiation. 18, 19 In order to form macrophages, granulocytes and B cells SPI1 levels must be exquisitely regulated. 20, 21 Our data, point to a SPI1/GFI1B axis regulating erythroid/myeloid commitment, which when dysregulated may play a role in leukemogenesis.
MATERIAL AND METHODS

Human Material
Human material and clinical information was obtained with informed consent and approval of institutional ethics committee.
Point mutation analysis
PCR fragments were analyzed by DHPLC as before (Supplementary Table 1 ).
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Target Region Capture Sequencing
Genomic DNA was randomly fragmented by Covaris (Woburn). DNA was amplified by ligation-mediated PCR (LM-PCR), purified, and hybridized to the NimbleGen (Roche) human custom array. High-throughput sequencing was performed with Hiseq2000 (Illumina).
Cloning
GFI1B cDNA was amplified with primers indicated in Supplementary Table 2, cloned in pGEM-T easy vector and sequenced. Point mutation was introduced by PCR. Wild-type or mutated coding cDNA was amplified from this plasmid with oligonucleotides shown in Supplementary Table 2 and cloned into pHRSINCSGW lentivirus vector, expressing green fluorescent protein (GFP). 23 The SPI1 hairpin has been published, 24 it was cloned into the SLX vector, 23 with or without wild-type or mutant GFI1B.
Lentivirus
Were prepared as described. 25 
Enrichment of hematopoietic stem and progenitors
Enrichment of CD34+ cells obtained from G-CSF mobilized adult human peripheral blood from patients undergoing autograft procedures for nonhematological disorders was by magnetic selection (Miltenyi Biotec).
Cord blood progenitors were isolated as described.
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Mobilised adult CD34+ cells and cord blood derived hematopoietic progenitors were maintained in MyeloCult® H5100 (StemCell Technologies) supplemented with 100ng/mL each human SCF, TPO, Flt3L (Peprotech).
Isolation of lentivirally transduced cells
Three days after lentiviral infection transduced cells were labeled with APC anti human CD34 (Cat 345802, BD Pharmingen) and CD34+/GFP+ cells were isolated using a Mo-Flo cell sorter (Dako).
MDS cell culture
Bone marrow mononuclear cells were enriched for CD34+ cells by magnetic separation and cultured in MyeloCult® H5100 with 10% (v/v) HS-5 conditioned medium, human SCF and IL-3 (both 50 ng/ml, Peprotech).
Methylcellulose Colony-Forming Cell (CFC) assays
CFC assays were in MethoCult H4436 (StemCell Technologies), 15 days. We performed 2 biological replicates for each experiment and plated 1000 cells in each experiment.
Liquid differentiation assays
These were performed in Myelocult® H5100 supplemented with human cytokines: SCF, FLT3L (both 50 ng/ml), IL-3, IL-6, GM-CSF, M-CSF (all 10 ng/ml): (Peprotech); G-CSF (0.1 MUI) (Ratiopharm); EPO (Amgen) (100 ng/ml)
Chromatin immunoprecipitation (ChIP) assay
ChIPs and immunoprecipitated DNA analysis were performed as previously described. 27-29 SPI1 promoter primers and probes are shown in Supplementary   Table 3 .
AML patients gene expression profiling and data analysis.
This has been published (www.ncbi.nlm.nih.gov/geo, GSE1159).
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Computational model
We applied deterministic rate equations. 3, 31 Additional information can be found in the Supplementary Methods and Supplementary Figure 1 .
RESULTS
A GFI1B zinc finger mutation arising on transformation of MDS into AML
Using DHPLC , we analyzed the GFI1B coding regions in DNA from the diagnostic bone marrow of 69 previously described patients with AML. 22 In this analysis, we identified a case with an abnormal pattern ( Figure 1A ).
Immunophenotyping data from the diagnostic bone marrow aspirate (which showed 48% blasts) are provided in Supplementary Table 4 . Bacterial cloning allowed the identification of a novel G>A mutation in exon six (position +3198 from the start codon, chromosome nine coordinate 135865264 GRCh37/hg19 assembly, NM_004188.5:c.784G>A), Figure 1B , in 12% of clones. This mutation is predicted to lead to an Asp (D) to Asn (N) transversion at aa262 (p.Asp262Asn), in the phylogenetically conserved fourth zinc finger motif of both GFI1B and GFI1 ( Figure 1C ). To accurately quantify the proportion of mutated DNA in the marrow, we performed a target region capture and next generation sequencing (NGS) of coordinates 135851000-135883000 chromosome nine GRCh37/hg19 assembly. This identifies the mutation in 13% of the total analysed DNA, corresponding to 26% of marrow cellularity. It is therefore, is a major clone in the leukemia (Supplementary Table 5 ). In contrast, we were unable to detect the mutation in samples taken some 18 months previously, when the patient initially presented with MDS, refractory anemia with excess blasts (RAEB), (Figure 1D-F) . This suggests that in this case, the acquisition of D262N is associated with disease progression.
GFI1B D262N impairs the function of the wild-type GFI1B.
To evaluate the impact of the GFI1B D262N (GFI1Bm) mutation we generated lentiviral vectors containing GFI1B and GFI1Bm under the control of either the spleen focus forming virus (CSI) or the Wiskott Aldrich Syndrome Protein promoters (CWI) allowing us to study the effects of relatively high (CSI) or low (CWI) levels of transgene over-expression ( Figure 2A ). Transduced cells were marked by an emerald-GFP reporter. GFP positive primary cells and cell lines were sorted and evaluated for expression of GFI1B targets.
GFI1B down-regulates its own expression. 28, 32 Consistent with this, we observed reduced levels of endogenous GFI1B mRNA after enforced expression of a GFI1B transgene in the leukemic cell line K562. This effect was proportional to transgene levels ( Figure 2B ) and similar results were obtained in primary CD34+ BM cells ( Figure 2C ). Enforced expression of GFI1Bm, in contrast, failed to repress endogenous GFI1B; indeed transcript levels increased ( Figure 2B , C). This effect was magnified by the increase in GFI1B expression ( Figure 2B ). These data are consistent with the notion that expression of GFI1Bm interferes with the repressor functions of wild-type GFI1B.
Functional antagonism of GFI1Bm on GFI1B was also observed in the derepression of other known GFI1B targets ( Figure 2D ).
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To explore mechanism of the differential effect of GFI1B and GFI1Bm on gene expression, we studied epigenetic marks within the endogenous GFI1B ( Figure   2E ) locus by ChIP in the hematopoietic cell line K562. Histone H3K4me3, associated with active transcription, 36 was significantly reduced at, and immediately downstream of, the endogenous promoter in cells transduced with GFI1B, but not GFI1Bm ( Figure 2F ). Consistent with previous observations, 28,37
H3K4me2 did not change ( Figure 2G ).
Taken together these results indicate that GFI1B D262N lacks the transcriptional repressor functions associated with the wild-type protein and that this alters histone methylation.
GFI1B D262N impacts lineage output from human primary hematopoietic cells
We tested the functional impact of GFI1Bm in hematopoiesis, by transducing primitive CD34+ cells derived from adult bone marrow with CWI or CSI based lentiviral vectors ( Figure 3A ) and assessing cell fate in vitro.
When CD34+ cells expressing GFI1Bm were maintained in liquid culture conditions that support multi-lineage differentiation, we observed a decrease in erythroid and an increase in myeloid output compared to cells transduced with wild-type GFI1B. This was assessed by expression of erythroid markers CD36
and CD235a and the myeloid marker CD13, Figure 3B .
Human CD34+ cells comprise several primitive hematopoietic progenitor types.
In order to further define the cells in which GFI1Bm has functional impact, we transduced cord-blood derived CMP (defined as CD34+38+10-7-135+45RA-, Supplementary Figure 2) . Consistent with our initial observations, GFI1Bm expression skewed lineage output towards myeloid in this compartment ( Figure   3C ). This shows that GFI1B D262N has a biological impact in highly purified bipotential progenitors. This skewing of lineage output was also seen in colony assays in methylcellulose with the same cytokines under conditions where total colony numbers were unaltered ( Figure 3D, Supplementary Figure 3 ).
We next explored the impact of GFI1Bm on progenitors under conditions that promote erythroid output. These results are presented in Figure 3E and show that expression of GFI1Bm also produces a reduction in erythroid output.
Transduction with the CWI construct driving lower expression levels revealed that this phenomenon was partly GFI1Bm dose dependent. The persistence of the erythroid differentiation bias under this experimental setting, which is closer to the physiological conditions, underlines the in vivo relevance of this finding.
GFI1B exhibits pro-apoptotic activity in human CD34+ cells. 38 Consistent with These data show that GFI1B D262N promotes the survival of normal human BM CD34+ cells and skews lineage output towards myeloid under conditions that support multilineage differentiation, implying a link between this mutation and the malignant phenotype.
Cross regulatory relationships of GFI1B and SPI1 in normal and AML cells
Although the GFI1B mutation we report is thus far restricted to a single case, we reasoned that the pathways that it dysregulates could have a wider role in AML. In support of this, analysis of transcriptional profiles from 285 previously characterized AMLs 30 revealed a striking inverse relationship in the patterns of GFI1B and SPI1 expression ( Figure 4A ). This suggests that GFI1B antagonizes SPI1 expression and that, simplistically at least, GFI1Bm could increase SPI1 levels. However, the presence of wild type and mutant GFI1B alleles in the same cell complicates the situation ( Figure 4B , C) and, therefore, we initially analyzed the behavior of this circuit in silico using a deterministic rate equation approach, 3, 31 (Supplementary Methods, Supplementary Figure 1 and Supplementary Table 7 ). Computational analysis indicates that even heterozygous expression of GFI1Bm enhances SPI1 expression ( Figure 4D ).
Manipulation of GFI1B expression in K562 cells provides concrete experimental evidence for this prediction ( Figure 4E ). Studies in primary human cells showed a similar trend ( Figure 4F ), small divergences between the two most likely reflect the inherent heterogeneity in primary cells.
Gfi1b binding to the Spi1 promoter in mouse, 39 suggests that the effects on SPI1 expression that we observed may in part stem from a direct regulation of SPI1 locus by GFI1B. We found a conserved GFI1B binding sequence at the same location in the human promoter ( Figure 4G ), and confirmed by ChIP that GFI1B binds to this site ( Figure 4H ).
We next explored the AML data set to ask what other molecular features correlated with high levels of SPI1 expression and observed a strong correlation with CD4 ( Figure 5A ). Interestingly, the leukemic blasts in the index case, were CD4+ (Supplementary Table 4 Taken together, these results suggest that high level SPI1 expression is associated with myelomonocytic affiliated AML samples. Expression of GFI1Bm dramatically enhances SPI1 expression and also results in up-regulation of the SPI1 target gene CD4. Interference with endogenous GFI1B activity is a plausible explanation for these findings.
The effects of GFI1B D262N are routed through SPI1
We tested whether the effects of GFI1Bm were mediated by increased SPI1 expression using a previously validated shRNA sequence. 24 With this reagent, we achieved knockdown of SPI1 RNA to approximately 15% of its starting level in adult human primary cells (CD13+/235-) ( Figure 6A ). We constructed a lentiviral vector containing this short-hairpin as well as either GFI1B or GFI1Bm under the control of an SFFV promoter. This strategy ensured co-expression within the same cells of the SPI1 shRNA and either the wild type or mutant GFI1B. These vectors were validated in K562 cells where SPI1 and GFI1B/GFI1Bm expression were simultaneously assessed ( Figure 6B ). The relative levels of SPI1 and GFI1B/GFI1Bm expression observed are consistent with the cross regulatory relationships we have proposed. Thus, total GFI1B levels are lower than those of GFI1Bm, consistent with its negativeautoregulatory behaviour. In contrast the extent of SPI1 knockdown observed is more marked in the GFI1B than the GFI1Bm setting, which is consistent with the proposed repressive role of GFI1B on SPI1.
We next transduced both adult mobilized CD34+ cells and cord blood derived CMPs with these 'dual' vectors and cultured them post transduction under cytokine conditions supportive of multineage differentiation, which was assessed with lineage-affiliated cell surface markers. Strikingly, and in both primary cell settings, knockdown of SPI1 activity, almost completely abrogated the lineage impact of GFI1Bm expression ( Figure 6 , C, D and E). Similarly, the effect of GFI1Bm on CD4 expression could be attenuated by SPI1 knockdown ( Figure 6F ). SPI1 has a half-life of approximately 70 hours. 42 We sorted CD34+/GFP+ cells 72 hours after lentivirus transduction and then cultured them for 5-6 days under differentaiting conditions before analyzing only the GFP+ cells. Thus, our experiments were performed more than 3 SPI1 protein half lives after viral transduction, thereby excluding the possibility residual endogenous protein could be interfering in our experiments. These results suggest that most -if not all -of GFI1Bm's activity in this experimental setting is routed through the master regulator SPI1.
DISCUSSION
Human cancer cells carry an extensive number of "driver" and neutral or "passenger" mutations. Through survey of gene expression data from primary AMLs we noted that leukemias with low GFI1B levels displayed high expression of SPI1, prompting us to test, and indeed prove, the hypothesis that the effects of this new mutation in GFI1B are routed through the nodal master regulator SPI1. From a mechanistic and transcriptional network perspective, these results suggest that pathways leading to enhanced expression of SPI1 may have a broad role in the pathogenesis of AML.
High levels of expression of GFI1B have been observed in some patients with leukemia and also in leukemic cell lines. 44, 45 However, the recent findings showing that Gfi1b is a direct repressor of oncogene Meis1 supports the notion that GFI1B can be involved in leukemia when its repressor function is abolished. 46 Other genes including SPI1. [47] [48] [49] [50] are associated with hematological malignancy both when up regulated and functionally inactivated This can be the case in proteins in which dose can have a deep impact on cell function and could explain the tight regulation of GFI1B expression level.
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Spi1 over expression produces erythroleukemia in mice. 47 Furthermore, SPI1 is over expressed in human KMT2A (MLL)-rearranged AMLs when compared to normal bone marrow CD34 cells, 49 and in mice, it has been shown to play an essential role in the initiation and maintenance of these leukemias. 49, 50 A subset of SPI1 target genes relevant to KMT2A leukemias is also regulated by MEIS1. 49 That GFI1B regulates both SPI1 and MEIS1 places it upstream in the same leukemogenic pathway. Therefore, our data uncover a previously unrecognized route to the dysregulation of SPI1 in AML. Recently, mutations in SPI1 have been found in 3 of 31 (10%) KMT2A-rearranged and 1 in 384 non-KMT2A-rearranged AMLs. 51 Two of the mutations in KMT2A leukemias were associated with reduced expression of SPI1 target genes. However, these authors did not find SPI1 among the genes whose expression level is altered in KMT2A AML compared to other AMLs. 51 These data underline the heterogeneity of AML, in which seemingly disparate subsets of patients may share specific transcriptional networks that could be therapeutically targeted.
The mutation described here appeared at the evolution of AML from a case of MDS, and it was not detectable during this earlier phase of the disease. NGS
indicates that it is present in 54% of leukemic cells. It is known that clonal heterogeneity is common in AML, importantly, different subclones are relevant at different stages of the disease, 52 and similarly new clonal events almost certainly drive the evolution of MDS to AML.
Although this is an infrequent mutation, we have demonstrated clear biological activity and a link between GFIB mutations and SPI1 deregulation. Our findings reinforce the importance of the SPI1 pathway in leukemogenesis.
CONCLUSIONS
Our data link GFI1B to both the myeloid and erythroid transcriptional networks 
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